These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10911615)

  • 1. Ribozyme as an approach for growth suppression of human pancreatic cancer.
    Kijima H; Scanlon KJ
    Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells.
    Tsuchida T; Kijima H; Oshika Y; Tokunaga T; Abe Y; Yamazaki H; Tamaoki N; Ueyama Y; Scanlon KJ; Nakamura M
    Biochem Biophys Res Commun; 1998 Dec; 253(2):368-73. PubMed ID: 9878544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
    Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
    Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.
    Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y
    Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture.
    Giannini CD; Roth WK; Piiper A; Zeuzem S
    Nucleic Acids Res; 1999 Jul; 27(13):2737-44. PubMed ID: 10373591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma.
    Tsuchida T; Kijima H; Hori S; Oshika Y; Tokunaga T; Kawai K; Yamazaki H; Ueyama Y; Scanlon KJ; Tamaoki N; Nakamura M
    Cancer Gene Ther; 2000 Mar; 7(3):373-83. PubMed ID: 10766343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells.
    Zhang YA; Nemunaitis J; Tong AW
    Mol Biotechnol; 2000 May; 15(1):39-49. PubMed ID: 10911621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes.
    Kita K; Saito S; Morioka CY; Watanabe A
    Int J Cancer; 1999 Feb; 80(4):553-8. PubMed ID: 9935156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
    Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.
    Irie A; Anderegg B; Kashani-Sabet M; Ohkawa T; Suzuki T; Halks-Miller M; Curiel DT; Scanlon KJ
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):341-9. PubMed ID: 10463078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line.
    Tokunaga T; Tsuchida T; Kijima H; Okamoto K; Oshika Y; Sawa N; Ohnishi Y; Yamazaki H; Miura S; Ueyama Y; Nakamura M
    Br J Cancer; 2000 Sep; 83(6):833-9. PubMed ID: 10952790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of the malignant phenotype by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
    Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme.
    Funato T; Shitara T; Tone T; Jiao L; Kashani-Sabet M; Scanlon KJ
    Biochem Pharmacol; 1994 Oct; 48(7):1471-5. PubMed ID: 7945447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo.
    Zhu H; Liang ZY; Ren XY; Liu TH
    Cancer Biol Ther; 2006 Dec; 5(12):1693-8. PubMed ID: 17106254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
    Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
    Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
    Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
    Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo].
    Liu G; Chen Y; Zhao X; Dong Y; Chen D
    Yi Chuan Xue Bao; 1996; 23(6):477-85. PubMed ID: 9084224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.
    Ohta Y; Kijima H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Nucleic Acids Res; 1996 Mar; 24(5):938-42. PubMed ID: 8600463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of EJ cells tumorigenicity.
    Tone T; Kashani-Sabet M; Funato T; Shitara T; Yoshida E; Kashfian BI; Horng M; Fodstadt O; Scanlon KJ
    In Vivo; 1993; 7(6A):471-6. PubMed ID: 8193263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.